MCID: BNG030
MIFTS: 51

Benign Ependymoma

Categories: Bone diseases, Cancer diseases, Neuronal diseases

Aliases & Classifications for Benign Ependymoma

MalaCards integrated aliases for Benign Ependymoma:

Name: Benign Ependymoma 12 15
Ependymoma 44 70
Who Grade Ii Ependymal Tumor 12
Myxopapillary Ependymoma 70
Epithelial Ependymoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4844
MeSH 44 D004806
NCIt 50 C3017
SNOMED-CT 67 443643007
UMLS 70 C0014474 C0205769

Summaries for Benign Ependymoma

MalaCards based summary : Benign Ependymoma, also known as ependymoma, is related to anaplastic ependymoma and papillary ependymoma, and has symptoms including back pain An important gene associated with Benign Ependymoma is TSC2 (TSC Complex Subunit 2), and among its related pathways/superpathways are Signaling by GPCR and Gene Expression. The drugs Etoposide and Thiotepa have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and pituitary, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Benign Ependymoma

Diseases in the Benign Ependymoma family:

Malignant Adult Ependymoma

Diseases related to Benign Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 489)
# Related Disease Score Top Affiliating Genes
1 anaplastic ependymoma 32.5 SYP PTEN NF2 GFAP
2 papillary ependymoma 32.2 SYP NF2 GFAP
3 high grade ependymoma 32.1 ZFTA NF2 KIAA1549 GFAP
4 clear cell ependymoma 32.1 ZFTA SYP NF2 GFAP
5 tanycytic ependymoma 32.0 ZFTA SYP NF2 GFAP
6 subependymoma 31.9 TSC2 SYP GFAP
7 medulloblastoma 31.0 TSC2 SYP PTEN NF1 MTOR GFAP
8 hydrocephalus 30.9 SYP PTEN MTOR GFAP
9 cauda equina syndrome 30.7 SYP GFAP
10 angiocentric glioma 30.6 SYP GFAP
11 malignant astrocytoma 30.6 PTEN NF1 KIAA1549 GFAP
12 neurilemmoma 30.5 NF2 NF1 GFAP
13 chordoma 30.4 PTEN MTOR GFAP
14 oligodendroglioma 30.3 SYP PTEN NF1 GFAP
15 rhabdoid meningioma 30.3 SYP NF2 GFAP
16 pleomorphic xanthoastrocytoma 30.2 SYP KIAA1549 GFAP
17 pineocytoma 30.2 SYP GFAP
18 meningioma, familial 30.1 SYP PTEN NF2 NF1 KIAA1549 GFAP
19 cystic teratoma 30.0 SYP PTEN GFAP
20 high grade glioma 29.9 PTEN NF1 MTOR GFAP
21 cellular ependymoma 29.9 ZFTA SYP NF2 GFAP
22 ganglioneuroma 29.9 SYP PTEN GFAP
23 myxopapillary ependymoma 29.9 ZFTA SYP NF2 GFAP
24 paraganglioma 29.9 SYP NF1 GFAP
25 pilocytic astrocytoma 29.9 SYP PTEN NF1 MTOR KIAA1549 GFAP
26 choroid plexus cancer 29.9 ZFTA SYP GFAP
27 cerebellar astrocytoma 29.9 NF1 KIAA1549
28 gliosarcoma 29.9 PTEN NF1 MTOR GFAP
29 lipomatosis, multiple 29.9 ZFTA PTEN NF1
30 atypical teratoid rhabdoid tumor 29.9 ZFTA SYP NF2 GFAP
31 glioblastoma 29.9 RPS6KB1 PTEN NF1 MTOR MIR323A GFAP
32 diffuse astrocytoma 29.8 NF1 KIAA1549 GFAP
33 spinal meningioma 29.8 NF2 NF1
34 obstructive hydrocephalus 29.8 TSC1 SYP NF2 NF1 MTOR GFAP
35 chordoid meningioma 29.8 SYP NF2 GFAP
36 clear cell meningioma 29.8 SYP NF2 GFAP
37 gangliocytoma 29.8 SYP PTEN KIAA1549 GFAP
38 renal cell carcinoma, nonpapillary 29.6 TSC2 TSC1 RHEB PTEN MTOR EIF4EBP1
39 ganglioglioma 29.6 TSC2 TSC1 SYP NF1 GFAP
40 gemistocytic astrocytoma 29.6 PTEN GFAP
41 giant cell glioblastoma 29.6 SYP PTEN MTOR GFAP
42 neuroma 29.5 NF2 NF1 GFAP
43 mixed glioma 29.5 PTEN NF1 GFAP
44 subependymal giant cell astrocytoma 29.5 TSC2 TSC1 SYP RHEB MTOR MIR323A
45 neurofibroma 29.5 SYP PTEN NF2 NF1
46 gliofibroma 29.5 SYP NF1 KIAA1549 GFAP
47 pilomyxoid astrocytoma 29.5 SYP NF1 KIAA1549 GFAP
48 brain cancer 29.4 SYP PTEN NF2 NF1 GFAP
49 spinal disease 29.3 PTEN NF1 KIAA1549 GFAP
50 spinal cancer 29.0 ZFTA SYP NF2 NF1 KIAA1549 GFAP

Graphical network of the top 20 diseases related to Benign Ependymoma:



Diseases related to Benign Ependymoma

Symptoms & Phenotypes for Benign Ependymoma

UMLS symptoms related to Benign Ependymoma:


back pain

GenomeRNAi Phenotypes related to Benign Ependymoma according to GeneCards Suite gene sharing:

26 (show all 34)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-11 10.18 MTOR RHEB
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 10.18 TSC1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-152 10.18 PTEN
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-16 10.18 MTOR RHEB
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-169 10.18 RICTOR
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.18 MTOR RHEB
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 10.18 TSC1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-206 10.18 TSC1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.18 RHEB
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 10.18 TSC1
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-42 10.18 MTOR RHEB RICTOR
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.18 MTOR
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-57 10.18 RHEB
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 10.18 RHEB
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-73 10.18 MTOR
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-82 10.18 TSC1
17 Decreased cell migration GR00055-A-1 9.97 NF2 RICTOR TSC1
18 Decreased cell migration GR00055-A-3 9.97 MTOR RICTOR
19 Decreased viability GR00055-A-1 9.93 MTOR
20 Decreased viability GR00055-A-2 9.93 MTOR
21 Decreased viability GR00221-A-1 9.93 MLST8 MTOR NF1 RHEB RPS6KB1
22 Decreased viability GR00221-A-2 9.93 NF1
23 Decreased viability GR00221-A-4 9.93 MLST8 MTOR NF1
24 Decreased viability GR00249-S 9.93 NF1
25 Decreased viability GR00301-A 9.93 RPS6KB1
26 Decreased viability GR00342-S-1 9.93 MTOR
27 Decreased viability GR00342-S-2 9.93 MTOR
28 Decreased viability GR00381-A-1 9.93 RPS6KB1
29 Decreased viability GR00386-A-1 9.93 NF1 RHEB
30 Decreased viability GR00402-S-2 9.93 RPS6KB1
31 Decreased sensitivity to paclitaxel GR00112-A-0 9.26 NF1 PTEN
32 Decreased viability with paclitaxel GR00179-A-1 9.02 MTOR RPS6KB1
33 Decreased viability with paclitaxel GR00179-A-2 9.02 MTOR
34 Decreased viability with paclitaxel GR00179-A-3 9.02 MTOR RPS6KB1

MGI Mouse Phenotypes related to Benign Ependymoma:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.29 EIF4EBP1 EPRS1 FKBP1A GFAP MTOR NF1
2 growth/size/body region MP:0005378 10.28 EIF4EBP1 EPRS1 FKBP1A GFAP MLST8 MTOR
3 cardiovascular system MP:0005385 10.27 EIF4EBP1 FKBP1A GFAP MLST8 MTOR NF1
4 embryo MP:0005380 10.27 EPRS1 FKBP1A MLST8 MTOR NF1 NF2
5 homeostasis/metabolism MP:0005376 10.24 EIF4EBP1 EPRS1 FKBP1A GFAP KIAA1549 MTOR
6 endocrine/exocrine gland MP:0005379 10.13 MTOR NF1 NF2 PTEN RHEB RICTOR
7 mortality/aging MP:0010768 10.13 EIF4EBP1 EPRS1 FKBP1A GFAP MLST8 MTOR
8 adipose tissue MP:0005375 10.11 EIF4EBP1 EPRS1 KIAA1549 MTOR PTEN RICTOR
9 liver/biliary system MP:0005370 9.92 FKBP1A NF1 NF2 PTEN RICTOR RPTOR
10 muscle MP:0005369 9.9 EIF4EBP1 FKBP1A GFAP MTOR NF1 PTEN
11 neoplasm MP:0002006 9.5 NF1 NF2 PTEN RICTOR RPS6KB1 TSC1
12 normal MP:0002873 9.28 EPRS1 FKBP1A GFAP MTOR NF1 PTEN

Drugs & Therapeutics for Benign Ependymoma

Drugs for Benign Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 181)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
2
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
3
Valproic acid Approved, Investigational Phase 2, Phase 3 99-66-1 3121
4
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
5
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
6
Trofosfamide Investigational Phase 2, Phase 3 22089-22-1
7 Etoposide phosphate Phase 2, Phase 3
8 Psychotropic Drugs Phase 2, Phase 3
9 Anticonvulsants Phase 2, Phase 3
10 Tubulin Modulators Phase 3
11 Antimitotic Agents Phase 3
12 Keratolytic Agents Phase 3
13 Podophyllotoxin Phase 3 518-28-5
14
Mesna Approved, Investigational Phase 2 3375-50-6 598
15
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
16
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 446556 60843
17
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
18
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
19
Ivosidenib Approved, Investigational Phase 2 1448347-49-6 71657455
20
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
21
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
22
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
23 Fenofibric acid Approved Phase 2 42017-89-0
24
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
25
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
26
Mebendazole Approved, Vet_approved Phase 2 31431-39-7 4030
27
Palbociclib Approved, Investigational Phase 2 571190-30-2 11431660 5005498 5330286
28
Piperazine Approved, Vet_approved Phase 2 110-85-0 4837
29
Olaparib Approved Phase 2 763113-22-0 23725625
30
Vemurafenib Approved Phase 2 918504-65-1 23252090 42611257
31
Memantine Approved, Investigational Phase 2 19982-08-2 4054
32
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
33
Vinblastine Approved Phase 2 865-21-4 13342 241903
34
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
35
nivolumab Approved Phase 1, Phase 2 946414-94-4
36
Iodine Approved, Investigational Phase 2 7553-56-2 807
37
carbamide peroxide Approved Phase 2 124-43-6
38
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
39
Bevacizumab Approved, Investigational Phase 2 216974-75-3
40
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
41
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
42
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
43
Lopinavir Approved Phase 2 192725-17-0 92727
44
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
45
Tryptophan Approved, Nutraceutical, Withdrawn Phase 2 73-22-3 6305
46
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
47
Methionine Approved, Nutraceutical Phase 2 63-68-3 6137
48
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
49
tipifarnib Investigational Phase 2 192185-72-1 159324
50
Ensartinib Investigational Phase 2 1370651-20-9

Interventional clinical trials:

(show top 50) (show all 149)
# Name Status NCT ID Phase Drugs
1 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
2 Therapy-Optimization Trial and Phase II Study for the Treatment of Relapsed or Refractory of Primitive Neuroectodermal Brain Tumors and Ependymomas in Children and Adolescents Completed NCT00749723 Phase 2, Phase 3 carboplatin;etoposide;temozolomide;thiotepa, carboplatin, etoposide;temozolomide, thiotepa;intraventricular etoposide;trofosfamide, etoposide
3 An International Clinical Program for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Ependymoma Recruiting NCT02265770 Phase 2, Phase 3 16 weeks of VEC + CDDP;VEC + HD-MTX;Chemotherapy + Valproate;VEC;Chemotherapy
4 Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years Active, not recruiting NCT01096368 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Etoposide;Vincristine
5 Phase II Study of High-Dose Methotrexate in Children With Residual Ependymoma Unknown status NCT00287924 Phase 2 methotrexate
6 Phase II Study of Intravenous Etoposide in Patients With Relapsed Ependymoma Unknown status NCT00278252 Phase 2 etoposide
7 Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
8 Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy Completed NCT00463203 Phase 2 Bevacizumab;Irinotecan
9 A Phase II Trial of Conformal Radiation Therapy for Pediatric Patients With Localized Ependymoma, Chemotherapy Prior to Second Surgery for Incompletely Resected Ependymoma and Observation for Completely Resected, Differentiated, Supratentorial Ependymoma Completed NCT00027846 Phase 2 carboplatin;cyclophosphamide;etoposide;vincristine sulfate;Mesna
10 A Phase II Study of Sunitinib (NSC# 736511) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients Completed NCT01462695 Phase 2 Sunitinib Malate
11 A Phase II Study of Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma Completed NCT00883688 Phase 2 Bevacizumab;Lapatinib
12 A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma Completed NCT00826241 Phase 2 Temozolomide;Lapatinib
13 SIOP Study of Combined Modality Treatment in Childhood Ependymoma Completed NCT00004224 Phase 2 cyclophosphamide;etoposide;vincristine sulfate
14 A Phase II Trial of Preradiation Multiagent Chemotherapy for Adults With "Poor Risk" Medulloblastoma, PNET, and Disseminated Ependymoma Completed NCT00003309 Phase 2 cisplatin;cyclophosphamide;etoposide;vincristine sulfate
15 Molecular Biology and Phase II Study of Lapatinib (GW572016) in Pediatric Patients With Recurrent or Refractory Medulloblastoma, Malignant Glioma or Ependymoma Completed NCT00095940 Phase 1, Phase 2 lapatinib ditosylate
16 Dose Intensive Chemotherapy for Patients Greater Than or Equal To 10 Years of Age With Newly Diagnosed High Stage Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors (PNET) and Ependymoma: A Feasibility Study of an Intensive Induction Chemotherapy Regimen Followed by Standard Irradiation Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
17 CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectodermal Tumors (PNET) That Have Either Progressed After Primary Therapy Or Are Refractory To Standard Chemotherapy Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
18 Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas Completed NCT00381797 Phase 2 Irinotecan Hydrochloride
19 A PHASE II TRIAL OF ETOPOSIDE AND CISPLATIN IN THE TREATMENT OF RECURRENT EPENDYMOMAS Completed NCT00002876 Phase 2 cisplatin;etoposide
20 Proton Radiation for Low Grade Gliomas Completed NCT01024907 Phase 1, Phase 2
21 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
22 A Phase II Study of Pemetrexed in Children With Recurrent Malignancies Completed NCT00520936 Phase 2 pemetrexed
23 Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas Completed NCT01125046 Phase 2
24 A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors Completed NCT00091182 Phase 2 oxaliplatin
25 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
26 Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2) Recruiting NCT04374305 Phase 2 Brigatinib
27 Phase 2 Trial of Indoximod With Chemotherapy and Radiation for Children With Progressive Brain Tumors or Newly Diagnosed DIPG Recruiting NCT04049669 Phase 2 Indoximod;Indoximod;Temozolomide;Cyclophosphamide;Etoposide;Lomustine
28 A Phase 2 Study of Abemaciclib in Patients With Recurrent Brain Tumors Recruiting NCT03220646 Phase 2 abemaciclib;abemaciclib
29 Phase II Clinical Trial of Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma Recruiting NCT03727841 Phase 2 Marizomib
30 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations Recruiting NCT04195555 Phase 2 Ivosidenib
31 Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center Trial Recruiting NCT01295944 Phase 2 Carboplatin;Bevacizumab
32 A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma, Ependymoma and ATRT Recruiting NCT01356290 Phase 2 Bevacizumab;Thalidomide;Celecoxib;Fenofibric acid;Etoposide;Cyclophosphamide;Etoposide phosphate;Cytarabine
33 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations Recruiting NCT03698994 Phase 2 Ulixertinib
34 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations Recruiting NCT04284774 Phase 2 Tipifarnib
35 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations Recruiting NCT04320888 Phase 2 Selpercatinib
36 Methionine PET/CT Studies In Patients With Cancer Recruiting NCT00840047 Phase 2 Methionine
37 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes Recruiting NCT03526250 Phase 2 Palbociclib
38 Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers Recruiting NCT03173950 Phase 2 Nivolumab
39 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes Recruiting NCT03233204 Phase 2 Olaparib
40 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations Recruiting NCT03220035 Phase 2 Vemurafenib
41 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions Recruiting NCT03213704 Phase 2 Larotrectinib;Larotrectinib Sulfate
42 NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors Recruiting NCT03213678 Phase 2 Samotolisib
43 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations Recruiting NCT03213652 Phase 2 Ensartinib
44 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients With Tumors Harboring FGFR1/2/3/4 Alterations Recruiting NCT03210714 Phase 2 Erdafitinib
45 Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors: A Pilot Study Recruiting NCT03194906 Phase 2 Memantine
46 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;Palbociclib;Samotolisib;Selpercatinib;Selumetinib Sulfate;Tazemetostat;Tipifarnib;Ulixertinib;Vemurafenib
47 Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
48 A Phase II Study of Image-Guided Radiation Therapy for Pediatric CNS Tumors and Quantification of Radiation-Related CNS Effects Active, not recruiting NCT00187226 Phase 2
49 Phase II Study of Everolimus (RAD001, Afinitor®) for Children With Recurrent or Progressive Ependymoma Active, not recruiting NCT02155920 Phase 2 Everolimus
50 A Phase II Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma Active, not recruiting NCT02125786 Phase 2 ^1^8F-Fluorodeoxyglucose;^1^1C-methionine

Search NIH Clinical Center for Benign Ependymoma

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Carmustine

Cochrane evidence based reviews: ependymoma

Genetic Tests for Benign Ependymoma

Anatomical Context for Benign Ependymoma

MalaCards organs/tissues related to Benign Ependymoma:

40
Spinal Cord, Brain, Pituitary, Pineal, Endothelial, Medulla Oblongata, Bone

Publications for Benign Ependymoma

Articles related to Benign Ependymoma:

(show top 50) (show all 3899)
# Title Authors PMID Year
1
Methylation and molecular profiles of ependymoma: Influence of patient age and tumor anatomic location. 61
33767857 2021
2
Bevacizumab as a surgery-sparing agent for spinal ependymoma in patients with neurofibromatosis type II: Systematic review and case. 61
33775351 2021
3
A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase-Clinical Trial Network (PEP-CTN). 61
33438318 2021
4
Intramedullary spinal cord tumours - a single Centre, 10-year review of clinical and pathological outcomes. 61
32441154 2021
5
Bioinformatics analysis of microarray data reveals epithelial-mesenchymal-transition in pediatric ependymoma. 61
33595943 2021
6
The role of clinical factors and immunocheckpoint molecules in the prognosis of patients with supratentorial extraventricular ependymoma: a single-center retrospective study. 61
33387039 2021
7
Solid-cystic cortical ependymoma: a diagnostic dilemma. 61
33404714 2021
8
[Spinal tumors]. 61
33570679 2021
9
Residential Proximity to Pesticide Application as a Risk Factor for Childhood Central Nervous System Tumors. 61
33798513 2021
10
Postoperative facial palsy after pediatric posterior fossa tumor resection. 61
33711807 2021
11
A Diagnostic Algorithm for Posterior Fossa Tumors in Children: A Validation Study. 61
33664107 2021
12
Differentiation Between Ependymoma and Medulloblastoma in Children with Radiomics Approach. 61
32222329 2021
13
Recent Advances in Understanding the Role of Autophagy in Paediatric Brain Tumours. 61
33803216 2021
14
RELA Fusion-Positive Ependymoma in a Child with Down Syndrome: A Case Report. 61
33690230 2021
15
Intra-fourth-ventricular choroid plexus papilloma miming ependymoma. 61
33763674 2021
16
YAP1-FAM118B Fusion Defines a Rare Subset of Childhood and Young Adulthood Meningiomas. 61
33074854 2021
17
Distinct circular RNA expression profiles in pediatric ependymomas. 61
33247464 2021
18
Outcome after treatment of spinal ependymoma in children and adolescents: long-term follow-up of a single consecutive institutional series of 33 patients treated over the period of eight decades. 61
33684583 2021
19
Supratentorial ependymoma in childhood: more than just RELA or YAP. 61
33481105 2021
20
ZFTA-RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma. 61
33741710 2021
21
ZFTA-translocations constitute ependymoma chromatin remodeling and transcription factors. 61
33741711 2021
22
High-grade neuroepithelial tumor with BCL6 corepressor-alteration presenting pathological and radiological calcification: A case report. 61
33713516 2021
23
Successful Multimodality Management of Atypical Teratoid/Rhabdoid Tumour of the Lower Dorsal Spine with Spinal Drop Metastasis: Illustrated Review. 61
33761503 2021
24
Surgical management of a huge intramedullary ependymoma from oblongata to T4: A case report. 61
33743243 2021
25
C11orf95-RELA fusion drives aberrant gene expression through the unique epigenetic regulation for ependymoma formation. 61
33685520 2021
26
Outcomes following limited-volume proton therapy for multifocal spinal myxopapillary ependymoma. 61
33226179 2021
27
TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma. 61
33755803 2021
28
A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. 61
33085768 2021
29
Postoperative Syrinx Shrinkage in Spinal Ependymoma of WHO Grade II. 61
33633066 2021
30
Recurring pediatric anaplastic ependymoma with rare peritoneal carcinomatosis: a case report and hypothesis of mechanism. 61
32681369 2021
31
Benefit of Static FET PET in Pretreated Pediatric Brain Tumor Patients with Equivocal Conventional MRI Results. 61
33598897 2021
32
Advances in the classification and treatment of pediatric brain tumors. 61
33278109 2021
33
Measurement of Apparent Diffusion Coefficient (ADC) Values of Ependymoma and Medulloblastoma Tumors: a Patient-based Study. 61
33564638 2021
34
Intraoperative consultation in the diagnosis of posterior fossa brain tumors following the 2016 WHO update. 61
33606311 2021
35
Analysis of the P53N a Novel Protein Encoded on Chromosome 22q12.1-12.3 in Glioblastomas and Ependymomas Specimens. 61
33595778 2021
36
Medulloblastoma: Clinical presentation. 61
31494131 2021
37
Ependymoma-like tumor with mesenchymal differentiation harboring C11orf95-NCOA1/2 or -RELA fusion: A hitherto unclassified tumor related to ependymoma. 61
33576087 2021
38
The Impact of Socioeconomic Status (SES) on Cognitive Outcomes Following Radiotherapy for Pediatric Brain Tumors: A Prospective, Longitudinal Trial. 61
33543269 2021
39
Molecular analysis of pediatric CNS-PNET revealed nosologic heterogeneity and potent diagnostic markers for CNS neuroblastoma with FOXR2-activation. 61
33536079 2021
40
Intracranial ependymomas: The role of advanced neuroimaging in diagnosis and management. 61
33525963 2021
41
Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. 61
33580238 2021
42
Extra-axial sacral soft tissue giant cell ependymoma affecting a child: Case report and review of the literature. 61
33569822 2021
43
The BET Inhibitor OTX015 Exhibits In Vitro and In Vivo Antitumor Activity in Pediatric Ependymoma Stem Cell Models. 61
33668642 2021
44
Retrosigmoid Approach for Resecting a Giant Lateral Pontine Ependymoma: Two-Dimensional Operative Video. 61
33717820 2021
45
Clinical characteristics and long-term surgical outcome of spinal myxopapillary ependymoma: a French cohort of 101 patients. 61
33624261 2021
46
Lumbar Laminoplasty for Resection of Myxopapillary Ependymoma of the Conus Medullaris: 2-Dimensional Operative Video. 61
33647943 2021
47
Pigmented Ependymoma of the Fourth Ventricle-A Curious Entity: Report of a Rare Case With Review of Literature. 61
32450730 2021
48
Outcomes after first relapse of childhood intracranial ependymoma. 61
33565268 2021
49
Abnormal spindle-like microcephaly-associated (ASPM) gene expression in posterior fossa brain tumors of childhood and adolescence. 61
32591873 2021
50
A Paravermal Trans-Cerebellar Approach to the Posterior Fossa Tumor Causes Hypertrophic Olivary Degeneration by Dentate Nucleus Injury. 61
33445527 2021

Variations for Benign Ependymoma

Expression for Benign Ependymoma

Search GEO for disease gene expression data for Benign Ependymoma.

Pathways for Benign Ependymoma

Pathways related to Benign Ependymoma according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.21 TSC2 TSC1 RPTOR RPS6KB1 RICTOR RHEB
2
Show member pathways
13.83 TSC2 TSC1 RPTOR RICTOR RHEB PTEN
3
Show member pathways
13.42 TSC2 TSC1 RPTOR RPS6KB1 RHEB PTEN
4
Show member pathways
13.14 TSC2 TSC1 RPTOR RHEB MTOR MLST8
5
Show member pathways
13.13 TSC2 TSC1 RPTOR RPS6KB1 RICTOR RHEB
6
Show member pathways
13.08 TSC2 TSC1 RPTOR RPS6KB1 RHEB PTEN
7
Show member pathways
13.05 TSC2 TSC1 RPTOR RICTOR RHEB PTEN
8
Show member pathways
12.97 TSC2 TSC1 RPS6KB1 RHEB MTOR EIF4EBP1
9
Show member pathways
12.96 TSC2 TSC1 RPTOR RPS6KB1 RHEB PTEN
10 12.81 TSC2 TSC1 RHEB MTOR EIF4EBP1
11
Show member pathways
12.8 TSC2 RPS6KB1 RHEB PTEN MTOR
12
Show member pathways
12.74 TSC2 RICTOR PTEN MTOR MLST8
13
Show member pathways
12.73 TSC2 TSC1 RPS6KB1 PTEN NF1 MTOR
14
Show member pathways
12.72 RPTOR PTEN MTOR MLST8 EIF4EBP1
15
Show member pathways
12.6 TSC2 TSC1 RPTOR RPS6KB1 RHEB MTOR
16
Show member pathways
12.53 RPS6KB1 PTEN NF1 MTOR EIF4EBP1
17
Show member pathways
12.51 TSC2 TSC1 RPS6KB1 RHEB MTOR EIF4EBP1
18
Show member pathways
12.5 TSC2 TSC1 RPS6KB1 RHEB PTEN MTOR
19
Show member pathways
12.5 TSC2 TSC1 RPTOR RPS6KB1 RICTOR RHEB
20
Show member pathways
12.47 RPS6KB1 PTEN MTOR EIF4EBP1
21
Show member pathways
12.45 RPTOR RPS6KB1 PTEN MTOR
22
Show member pathways
12.38 TSC2 RPS6KB1 PTEN MTOR EIF4EBP1
23 12.36 TSC2 TSC1 RPTOR RPS6KB1 RICTOR MTOR
24
Show member pathways
12.35 TSC2 TSC1 RPTOR RPS6KB1 RICTOR RHEB
25
Show member pathways
12.33 TSC2 TSC1 RPTOR RPS6KB1 MTOR EIF4EBP1
26 12.28 TSC2 TSC1 RHEB PTEN MTOR EIF4EBP1
27
Show member pathways
12.27 TSC2 RPS6KB1 RHEB MTOR
28 12.27 TSC2 TSC1 RHEB PTEN NF1 MTOR
29 12.26 RPS6KB1 RICTOR PTEN MTOR EIF4EBP1
30
Show member pathways
12.25 TSC2 TSC1 RPTOR RPS6KB1 RHEB MTOR
31
Show member pathways
12.25 TSC2 TSC1 RPTOR RPS6KB1 RICTOR RHEB
32 12.15 TSC2 RPS6KB1 MTOR EIF4EBP1
33 12.14 TSC2 TSC1 RPTOR RPS6KB1 RHEB PTEN
34
Show member pathways
12.12 TSC2 RPS6KB1 RHEB MTOR EIF4EBP1
35 12.1 TSC2 TSC1 RPS6KB1 PTEN NF2 NF1
36
Show member pathways
12.03 TSC2 TSC1 RPTOR RHEB MTOR MLST8
37 11.99 TSC2 TSC1 TBC1D7 RHEB PTEN
38 11.93 PTEN MTOR MLST8
39 11.93 TSC2 TSC1 RPTOR RHEB PTEN MTOR
40 11.91 RICTOR MTOR MLST8
41
Show member pathways
11.89 TSC2 RICTOR MTOR MLST8
42 11.85 RPS6KB1 MTOR EIF4EBP1
43
Show member pathways
11.83 TSC2 TSC1 TBC1D7 RPTOR RPS6KB1 RICTOR
44 11.77 RICTOR MTOR MLST8
45
Show member pathways
11.75 RICTOR MTOR MLST8
46 11.72 RPTOR RPS6KB1 MTOR MLST8 EIF4EBP1
47 11.71 RPS6KB1 MTOR EIF4EBP1
48 11.6 TSC2 TSC1 MTOR
49 11.59 TSC2 TSC1 RPTOR MTOR MLST8
50 11.54 TSC2 TSC1 TBC1D7

GO Terms for Benign Ependymoma

Cellular components related to Benign Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.21 TSC2 TSC1 RPTOR RPS6KB1 RHEB PTEN
2 cytosol GO:0005829 9.53 TSC2 TSC1 TBC1D7 RPTOR RPS6KB1 RICTOR
3 postsynaptic cytosol GO:0099524 9.43 PTEN MTOR EIF4EBP1
4 TORC2 complex GO:0031932 9.33 RICTOR MTOR MLST8
5 TSC1-TSC2 complex GO:0033596 9.32 TSC2 TSC1
6 TORC1 complex GO:0031931 9.13 RPTOR MTOR MLST8

Biological processes related to Benign Ependymoma according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.97 TSC2 TSC1 PTEN NF2 NF1
2 cellular response to insulin stimulus GO:0032869 9.85 RPS6KB1 PTEN EPRS1
3 regulation of translation GO:0006417 9.84 TSC1 RPS6KB1 EPRS1 EIF4EBP1
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.83 RICTOR MTOR MLST8
5 negative regulation of protein kinase activity GO:0006469 9.83 TSC2 NF2 NF1
6 regulation of cell cycle GO:0051726 9.83 TSC2 TSC1 PTEN NF2
7 negative regulation of translation GO:0017148 9.82 TSC1 EPRS1 EIF4EBP1
8 response to nutrient GO:0007584 9.81 RPS6KB1 PTEN MTOR
9 response to insulin GO:0032868 9.8 TSC1 RPS6KB1 MTOR
10 response to nutrient levels GO:0031667 9.8 TSC1 RPS6KB1 MTOR
11 regulation of cellular response to heat GO:1900034 9.79 RPTOR MTOR MLST8
12 regulation of actin cytoskeleton organization GO:0032956 9.78 RICTOR MTOR MLST8
13 cell cycle arrest GO:0007050 9.78 RPTOR RHEB MTOR MLST8
14 negative regulation of neuron projection development GO:0010977 9.77 TSC1 PTEN GFAP
15 positive regulation of endothelial cell proliferation GO:0001938 9.77 RPTOR RICTOR MTOR
16 positive regulation of stress fiber assembly GO:0051496 9.74 TSC1 NF2 MTOR
17 positive regulation of protein serine/threonine kinase activity GO:0071902 9.73 RPTOR RICTOR MLST8
18 positive regulation of actin filament polymerization GO:0030838 9.72 RICTOR MTOR MLST8
19 regulation of GTPase activity GO:0043087 9.71 RICTOR NF1 MTOR MLST8
20 protein kinase B signaling GO:0043491 9.69 TSC2 RPS6KB1 PTEN
21 negative regulation of phosphatidylinositol 3-kinase signaling GO:0014067 9.67 TSC2 PTEN
22 negative regulation of macroautophagy GO:0016242 9.67 TSC1 MTOR
23 negative regulation of insulin receptor signaling pathway GO:0046627 9.67 TSC2 TSC1 RPS6KB1
24 cellular response to nutrient levels GO:0031669 9.66 RPTOR MTOR
25 regulation of cell-matrix adhesion GO:0001952 9.66 TSC1 NF1
26 positive regulation of transcription by RNA polymerase III GO:0045945 9.64 RPTOR MTOR
27 anoikis GO:0043276 9.64 TSC2 MTOR
28 activation of protein kinase B activity GO:0032148 9.63 RICTOR MTOR MLST8
29 cellular response to leucine GO:0071233 9.62 RPTOR MTOR
30 regulation of macroautophagy GO:0016241 9.62 RPTOR RHEB MTOR MLST8
31 negative regulation of TOR signaling GO:0032007 9.61 TSC2 TSC1 TBC1D7
32 forebrain morphogenesis GO:0048853 9.58 PTEN NF1
33 regulation of protein kinase B signaling GO:0051896 9.54 RICTOR PTEN MTOR
34 negative regulation of cell size GO:0045792 9.43 TSC1 PTEN MTOR
35 TORC1 signaling GO:0038202 9.33 RPTOR MTOR MLST8
36 positive regulation of TOR signaling GO:0032008 9.26 RPTOR RICTOR RHEB MLST8
37 TOR signaling GO:0031929 9.1 RPTOR RPS6KB1 RICTOR MTOR MLST8 EIF4EBP1

Molecular functions related to Benign Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.72 RPTOR RICTOR RHEB PTEN MTOR
2 RNA polymerase III type 3 promoter sequence-specific DNA binding GO:0001006 9.26 RPTOR MTOR
3 TFIIIC-class transcription factor complex binding GO:0001156 9.16 RPTOR MTOR
4 RNA polymerase III type 2 promoter sequence-specific DNA binding GO:0001003 8.96 RPTOR MTOR
5 RNA polymerase III type 1 promoter sequence-specific DNA binding GO:0001002 8.62 RPTOR MTOR

Sources for Benign Ependymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....